April 26th 2024
During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed the intracranial efficacy of brigatinib from the ALTA-1L trial for patients with ALK+ non–small cell lung cancer in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Phase 2 of ARROS-1 Trial Assessing NVL-520 in Solid Tumors Commences
September 5th 2023As determined by phase 1 of the ARROS-1 study, patients with ROS1-positive non–small cell lung cancer and other solid tumors will be further assessed with the recommended phase 2 dose of NVL-520 in phase 2 of the trial.
Read More
ALINA Study of Alectinib Meets Primary DFS End Point in ALK+ NSCLC
September 1st 2023Alectinib is the first and only ALK inhibitor to demonstrate a reduction in disease recurrence among patients with early-stage ALK-positive non–small cell lung cancer, based on data from the phase 3 ALINA study.
Read More
The Growing Role of Immunotherapy in Targeting NSCLC
August 30th 2023During a Targeted Oncology™ Community Case Forum™ event in partnership with The Arizona Clinical Oncology Society, Sujith R. Kalmadi, MD, reviewed data from the most important recent phase 3 trials of chemoimmunotherapy in advanced non–small cell lung cancer.
Read More
Patient Characteristics Influence Choice of Chemo/IO Regimen in NSCLC
August 24th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Sandip P. Patel, MD, discussed the importance of patient characteristics and biomarkers in choosing an immunotherapy-containing regimen for patients with non–small cell lung cancer, particularly if their PD-L1 expression is low. This is the first of 2 articles based on this event.
Read More
Amivantamab Plus Lazertinib May Be a Future Treatment Option for NSCLC
August 17th 2023In an interview with Targeted Oncology, Se-Hoon Lee, MD, highlights the results of the long-term analysis of the CHRYSALIS trial looking at amivantamab and lazertinib for patients with EGFR mutated non–small cell lung cancer.
Read More
Use of ICI Therapy Beyond 2 Years Yields No Outcome Benefit in NSCLC
August 10th 2023Findings from a study published in JAMA Oncology showed no survival difference in fixed duration immune checkpoint inhibitor group vs the indefinite-duration group among patients with non–small cell lung cancer
Read More
Efficacy and Safety of Tusa with Pembrolizumab and Chemotherapy in NSCLC: CARMEN-LC05 Study
August 8th 2023Important findings from the CARMEN-LC05 study evaluating tusa in combination with pembrolizumab and chemotherapy in NSCLC are discussed, highlighting their implications for clinical practice.
Watch
Counseling Patients on Next Steps After Chemoradiation for Stage III NSCLC
July 17th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Garrett B. Sherwood, MD, discussed with participants what therapy to use, including adjuvant immunotherapy, for a patient with stage III non–small cell lung cancer. This is the second of 2 articles based on this event.
Read More
Kelly Explores Current Immunotherapy/Chemotherapy Combinations in NSCLC
July 13th 2023During a Targeted Oncology™ Clinical Case Forum™ event, Ronan J. Kelly, MD, MBA, discussed the significance of the CheckMate 9LA, KEYNOTE-407, EMPOWER-Lung 3, and POSEIDON studies which all explored immunotherapies in patients with advanced non–small cell lung cancer.
Read More
ADAURA: Overall Survival Analysis of Osimertinib in NSCLC
July 7th 2023Charu Aggarwal, MD, MPH, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data updates from the ADAURA trial, an overall survival analysis of osimertinib in non–small cell lung cancer (NSCLC).
Watch